Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

Also called NCT01876368

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 376 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01876368
  • EudraCT 2013-001783-36
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Guatemala, Philippines, Puerto Rico, Russia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01876368. Randomized; double masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-12-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
Condition
Hypertension
Intervention (Drug)
LCZ696
Intervention (Drug)
Olmesartan
Intervention (Drug)
Placebo of LCZ696
Intervention (Drug)
Placebo of Olmesartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01876368
Content hash
5c4923eac9f85ab71f1ba8b1231a5af0dd971bde392b81d96b4c2694c514df51